Areas of Focus:

Academia–Industry PartnershipsAdaptive ImmunityBiological & MechanisticCollaboration & InnovationExperimental Platforms & ModelsT Cell BiologyTherapeutic DevelopmentTranslational & ClinicalCross-Cutting & Special Populations
  • Professor, Department of Microbiology, Perelman School of Medicine, University of Pennsylvania

Dr. James Riley is a Professor of Microbiology at the Perelman School of Medicine, University of Pennsylvania, and a senior investigator at the Center for Cellular Immunotherapies. He received his BS from Vanderbilt University and his PhD from Emory University, completing postdoctoral training that built the foundation for his career in human T cell engineering.

The Riley laboratory is internationally recognized for its work on engineered T cell therapies, including pioneering development of CAR-T cell approaches for HIV cure strategies as a co-founder of Tmunity Therapeutics. His group continues to advance fundamental and translational T cell biology, with active programs at the interface of infectious disease, cancer immunotherapy, and autoimmunity.

Dr. Riley is a longstanding faculty leader within the Center for Cellular Immunotherapies and a member of the Penn Colton Center for Autoimmunity, where his expertise in adoptive cellular therapy intersects directly with Penn’s growing program in CAR-T for autoimmune disease. He partners broadly with industry to advance translational cell therapy platforms.

Projects

Featured Pilot Projects

Center of Excellence for Cell Therapy in Autoimmunity (CECTA)
Project | University of Pennsylvania

Center of Excellence for Cell Therapy in Autoimmunity (CECTA)

Advancing engineered CAR and CAAR T cell therapies across multiple autoimmune diseases through clinical trials, preclinical development, and industry partnerships.